murepavadin + colistimethate sodium

**Murepavadin + colistimethate sodium** is a combination of two agents: murepavadin, a novel, investigational peptidomimetic antibiotic targeting *Pseudomonas aeruginosa* by binding to the outer membrane protein LptD and inhibiting lipopolysaccharide transport; and colistimethate sodium (colistin methanesulfonate sodium), a polymyxin antibiotic that disrupts bacterial cell membrane integrity. This combination is under clinical investigation for the treatment of multidrug-resistant Gram-negative bacterial infections, particularly hospital-acquired and ventilator-associated pneumonia due to *Pseudomonas aeruginosa*. Murepavadin is being developed primarily as an intravenous agent, while colistimethate sodium can be administered intravenously or by inhalation[1][2][3].

Other names

murepavadin + colistin methanesulfonate sodiummurepavadin + colistimethate sodium